Subjects: CÉLULAS-TRONCO, ESCLEROSE MÚLTIPLA
ABNT
BURT, Richard K. et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. Jama, v. 321, n. 2, p. 165-174, 2019Tradução . . Disponível em: https://doi.org/10.1001/jama.2018.18743. Acesso em: 02 nov. 2024.APA
Burt, R. K., Balabanov, R., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., et al. (2019). Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. Jama, 321( 2), 165-174. doi:10.1001/jama.2018.18743NLM
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial [Internet]. Jama. 2019 ; 321( 2): 165-174.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1001/jama.2018.18743Vancouver
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial [Internet]. Jama. 2019 ; 321( 2): 165-174.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1001/jama.2018.18743